+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

EHA-ASH Translational Research Training in Hematology (TRTH) program

American Society of Hematology

The TRTH program includes an intensive week-long course held in the spring (the Spring Course) and year-long mentoring interaction with experts in the field. Mornings are dedicated to research seminar-style interactive sessions on translational and basic science research methodology, cutting-edge technology, and career development. Afternoons are devoted to small group sessions in which participants meet with their TRTH mentors, peers, and faculty to refine their individual research proposals and hone their scientific presentation and communication skills. Informal presentations by leaders in hematology, designed to illustrate the variety of pathways to a successful career in blood-related lab-based research, take place in the evenings. After this initial course, follow-up mentoring meetings occur throughout the year at the annual EHA Congress and ASH meetings.

During the Spring Course, mornings are dedicated to research seminar-style interactive sessions on translational and basic science research methodology, cutting-edge technology, and career development. Afternoons are devoted to small group sessions in which participants meet with their TRTH mentors, peers, and faculty to refine their individual research proposals and hone their scientific presentation and communication skills. Informal presentations by leaders in hematology, designed to illustrate the variety of pathways to a successful career in blood-related, lab-based research, take place in the evenings. After this initial course, follow-up mentoring meetings occur throughout the year at the annual EHA and ASH meetings.

Spring Course

The Spring Course includes the following main components:

Principles of translational and basic science research: Participants will discuss methodologies for designing and executing clinical research studies with laboratory correlatives. Topics include stem cell research, animal models, live cell and in vivo imaging, flow cytometry, cell therapy, cell and biobanking, clinical trial design, principles of bioinformatics, molecular pathogenesis (including genetics, gene editing and epigenetics), pharmacogenomics, diagnostics and biomarkers, and identification of molecular targets.
Ethics in hematologic translational and basic science research: Discussions focus on ethical and regulatory issues in Europe and North America related to translational and basic science research. Topics include good clinical practice, quality care assurance, good manufacturing practice, relationships with the pharmaceutical and biotech industry, and intellectual property.
Career development insight: Career retrospectives are provided from leading hematologists with broad experience in translational and basic science research. Hematology pioneers speak about their personal and career challenges and successes as well as maintaining a work-life balance.
Breakout group sessions: These daily sessions enable participants to refine their research projects with each other and faculty. The sessions allow participants to forge bonds for collaboration and in-depth improvements of their research proposals.
Presentation of research proposals: The course begins with participants sharing their initial research proposals. On the final day of the program, they present updated proposals that reflect the adjustments made during the week.

Learning objectives

TRTH offers trainees the opportunity to:

Discuss the principles of translational and basic science research design and execution.
Recognize the ethical and regulatory issues of translational and basic science research.
Examine the fundamentals of competitive grant writing, abstract presentation, and manuscript preparation.
Improve the quality of research proposals through input from faculty and peers.
Formulate strategies for pursuing and developing a successful career in hematology and blood-related research.
Discuss approaches to forming and sustaining a multi-disciplinary translational and basic science research team.
Practice preparing research results and efficiently presenting it to diverse audiences.
Network and develop relationships with other participants to facilitate future collaboration.
Develop relationships with leaders in translational, basic science, and clinical research who can enhance professional networking opportunities.

AI Based Application Success Predictor

1. Direct relevance to hematology (highest predictor)

This is the most important success factor.

Competitive proposals should focus on benign or malignant hematologic diseases and related areas, including:

Leukemia
Lymphoma
Multiple myeloma
Myelodysplastic syndromes
Myeloproliferative neoplasms
Sickle cell disease
Hemophilia and bleeding disorders
Thrombosis and hemostasis
Bone marrow failure
Stem cell biology and transplantation
Transfusion medicine
Immunohematology

Projects outside hematology are generally not competitive.

2. Scientific excellence and significance (very high predictor)

ASH consistently emphasizes funding research that addresses important unanswered questions in hematology.

Competitive proposals should demonstrate:

A compelling scientific question
Strong biological or clinical rationale
High potential impact
Importance to the hematology community
Ability to advance knowledge or patient care

Scientific significance is a central review criterion across ASH award programs.

3. Innovation and originality (very high predictor)

Competitive applications often include:

Novel biological mechanisms
Innovative therapeutic approaches
Precision hematology
Advanced genomics
Gene editing
Cell therapies
Artificial intelligence
New biomarkers
Innovative clinical trial designs

Projects that substantially advance the field are favored over incremental studies.

4. Strong translational or clinical relevance (very high predictor)

ASH supports research across the continuum from laboratory discovery to patient care.

Competitive proposals often involve:

Translational research
Early-phase clinical trials
Biomarker validation
Precision medicine
Implementation science
Comparative effectiveness research

Even basic science projects are strengthened by a clear pathway toward clinical application.

5. Rigorous methodology and feasibility (very high predictor)

Successful proposals typically include:

Clearly defined hypotheses
Appropriate study design
Robust statistical analysis
Feasible recruitment (if clinical)
Realistic milestones
Appropriate outcome measures

Methodological rigor is essential for all ASH funding mechanisms.

6. Outstanding investigator potential (very high predictor)

For programs such as the ASH Scholar Awards, reviewers strongly evaluate the applicant's long-term promise.

Competitive applicants demonstrate:

High-quality publications
Strong research productivity
Leadership potential
Commitment to hematology research
Clear trajectory toward independence

Applicant potential is particularly important for fellows and early-career faculty.

7. Excellent mentorship and institutional support (very high predictor)

Mentorship is a major review criterion for early-career awards.

Competitive applications include:

Experienced mentor(s)
Comprehensive mentoring plan
Protected research time
Strong institutional commitment
Access to patients, laboratories, or core facilities

For Scholar Awards, reviewers evaluate whether the environment will enable the applicant's long-term success.

8. Potential for future independent funding (high predictor)

Many ASH awards are intended to launch independent investigators.

Competitive proposals explain how the project will:

Generate preliminary data
Support NIH or equivalent grant applications
Establish an independent laboratory or clinical research program
Lead to multicenter studies

A clear long-term funding strategy strengthens the application.

9. Commitment to diversity, equity, and global hematology (high predictor)

ASH supports initiatives to improve diversity within hematology and strengthen hematology research globally.

Projects addressing:

Health disparities
Underrepresented populations
Global hematology
Access to care
Workforce diversity

may align particularly well with specific ASH funding opportunities.

10. Dissemination and impact on hematology practice (high predictor)

Competitive projects should demonstrate potential to:

Publish in leading hematology journals
Present at ASH Annual Meetings
Influence clinical guidelines
Improve standards of care
Advance evidence-based hematology

Projects capable of changing clinical practice are especially attractive.

Specialties

Hematology

Eligibility Requirements

Applicants must be a trainee or junior faculty and hold an MD and/or PhD or biomedical PhD or pharmacy PharmD degree (or equivalents) in basic and translation research in classical or malignant hematology. Additionally, the following time limits apply:

MD applicants must be within 12 years of graduation at the time of the deadline for full application.
PhD applicants must have less than 8 years of post-doc experience after graduation at the time of the deadline for full application.
Applicants holding both an MD and a PhD must be within 12 years of MD graduation.

Exceptions may be made for interruptions in an applicant’s academic pursuits. If you would like to request an exception, please, contact training@ehaweb.org. The applicant must also explain the circumstances of the interruption in the application.

Applicants must be actively employed in a hematology or hematology-related research environment. Proficiency in English (written and spoken) is required.

Life events

For each child/pregnancy, a mother can add 18 months to the time since graduation, and a father can add 3 months.
Other life events, e.g., military service, disease, or lab closure, can also extend the period of eligibility but must be justified. If you have doubts regarding your eligibility, please contact the EHA office at training@ehaweb.org.

Project eligibility

The focus of the TRTH program is on laboratory-based translational research in hematology fields. Research projects must be hypothesis-driven and directly connected to some aspects of human biology.

Projects may encompass any form of cellular, molecular, structural, biochemical, genetic, or other appropriate experimental approach using human biological material or human subjects with the aim of reaching novel insights into human biology.

Pilot and early phase clinical studies translating the laboratory discoveries “to the bedside” may be included in the proposal, however, pure clinical trial projects with laboratory correlatives will not be considered.

Sponsor Details

Sponsor Institute/Organizations: American Society of Hematology

Sponsor Type: Corporate/Non-Profit

Address: 2021 L Street NW, Suite 900, Washington, DC 20036

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity